[Action of "essential" phospholipids on plasma lipids and fatty acids in type II hyperlipoproteinemias].
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy; D001797:Blood Protein Electrophoresis; D002784:Cholesterol / Q000097:blood; D005227:Fatty Acids / Q000097:blood*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008041:Linoleic Acids / Q000097:blood; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009829:Oleic Acids / Q000097:blood; D010713:Phosphatidylcholines / Q000097:blood; D010743:Phospholipids / Q000627:therapeutic use*
D005227:Fatty Acids; D008041:Linoleic Acids; D008055:Lipids; D008074:Lipoproteins; D009829:Oleic Acids; D010713:Phosphatidylcholines; D010743:Phospholipids; D002784:Cholesterol
Wirkung der "essentiellen" Phospholipide auf Plasmalipide und Fettsäuren beim TyP II der Hyperlipoproteinaämie.